Use of hormone replacement therapy and the risk of colorectal cancer.
OBJECTIVE
Estrogen/progestin replacement therapy is prescribed to women in menopause for purposes of postmenopausal symptom control or prevention of hormone deficiency-related diseases such as osteoporosis. Such treatments have formerly been shown to be associated with lower colorectal cancer risk in an as yet unknown mechanism.


METHODS
The Molecular Epidemiology of Colorectal Cancer study was a population-based case-control study in northern Israel of patients with colorectal cancer who were diagnosed between 1998 and 2006, and age-, sex-, clinic-, and ethnicity-matched population controls. Use of hormone replacement therapy (HRT) was assessed using a structured interview and validated by studying prescription records in a subset of patients for whom they were available.


RESULTS
Two thousand four hundred sixty peri/postmenopausal women were studied from among 2,648 patients with colorectal cancer and 2,566 controls. The self-reported use of HRT was associated with a significantly reduced relative risk of colorectal cancer (odds ratio [OR], 0.67; 95% CI, 0.51 to 0.89). This association remained significant after adjustment for age, sex, use of aspirin and statins, sports activity, family history of colorectal cancer, ethnic group, and level of vegetable consumption (OR, 0.37; 95% CI, 0.22 to 0.62). Statistically significant interactions were seen between use of HRT and use of aspirin and involvement in sports activity. Using pharmacy data, only users of combined oral preparations demonstrated a significant negative association with colorectal cancer.


CONCLUSIONS
The use of oral HRT was associated with a 63% relative reduction in the risk of colorectal cancer in postmenopausal women after adjustment for other known risk factors. This effect was not found in aspirin users and women with intensive sports participation.
Rennert
Gad
G
Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal St, Haifa 34362, Israel. rennert@tx.technion.ac.il
Rennert
Hedy S
HS
Pinchev
Mila
M
Lavie
Ofer
O
Gruber
Stephen B
SB
D000368:Aged; D015179:Colorectal Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D047648:Perimenopause; D017698:Postmenopause; D012307:Risk Factors
JAMA. 2002 Aug 21;288(7):872-81
12186605
JAMA. 2005 Jan 19;293(3):330-9
15657326
Am J Gastroenterol. 2005 Aug;100(8):1813-20
16086719
N Engl J Med. 2004 Mar 4;350(10):991-1004
14999111
Dis Colon Rectum. 2005 Dec;48(12):2317-21
16228836
PLoS Med. 2007 May;4(5):e157
17518513
Br J Cancer. 2004 Jan 12;90(1):76-81
14710210
JAMA. 2004 Apr 14;291(14):1701-12
15082697
Osteoporos Int. 1998;8(6):540-6
10326058
BMJ. 2008 Jul 10;337:a386
18617493
Hum Reprod. 2007 Jun;22(6):1769-77
17347166
Br J Cancer. 2007 Dec 3;97(11):1486-92
17987040
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Int J Cancer. 2003 Jun 20;105(3):408-12
12704678
CMAJ. 2000 May 16;162(10):1421-4
10834045
Gastroenterology. 1993 Jul;105(1):142-7
8514031
Ann Oncol. 2008 Jan;19(1):150-5
17785762
Menopause. 2007 Nov-Dec;14(6):985-94
17507833
Cancer Causes Control. 2005 Oct;16(8):965-73
16132805
Ann Intern Med. 2001 Oct 2;135(7):493-501
11578152
J Aging Phys Act. 2004 Oct;12(4):554-67
15851826
Carcinogenesis. 2008 Sep;29(9):1774-80
18375958
Gastroenterology. 2001 Sep;121(3):542-7
11522737
N Engl J Med. 2005 May 26;352(21):2184-92
15917383
Cancer Causes Control. 2003 Dec;14(10):979-84
14750537
Contraception. 2005 Feb;71(2):95-8
15707557
Lancet. 2002 Sep 21;360(9337):942-4
12354487
Cancer Res. 2001 Jan 1;61(1):126-30
11196149
Cancer Res. 2007 Aug 1;67(15):7534-9
17671225
Obstet Gynecol. 1994 Jan;83(1):5-11
8272307
Int J Vitam Nutr Res. 2007 Nov;77(6):398-405
18622950
Am J Clin Nutr. 1982 Nov;36(5):936-42
7137077
J Cell Mol Med. 2007 Sep-Oct;11(5):1138-48
17979889
Eur J Cancer Prev. 2005 Aug;14(4):373-9
16030428
Cancer Causes Control. 1997 Mar;8(2):146-58
9134238
Obstet Gynecol. 1999 May;93(5 Pt 2):880-8
10912438